Fig. 1: Effect of gemcitabine and/or TRAIL on PDAC survival. BxPC-3, MIA PaCa-2 and PANC-1 cells were seeded in 96-well plates at a cell seeding density of 3x104 cells/cm2 | Cell Death & Disease

Fig. 1: Effect of gemcitabine and/or TRAIL on PDAC survival. BxPC-3, MIA PaCa-2 and PANC-1 cells were seeded in 96-well plates at a cell seeding density of 3x104 cells/cm2

From: Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL

Fig. 1

a Sensitivity of cells to gemcitabine was assessed by MTT assay. Cells were treated with increasing amounts of gemcitabine (0.001–1000 μM) for 24 h (n = 4). b Sensitivity of cells to TRAIL was assessed by MTT assay. Cells were treated with increasing amounts of TRAIL (0.001–1000 ng/ml) for 4 h (n = 4). c–e Sensitivity of cells to gemcitabine and TRAIL combination treatment was assessed by MTT assay. Cells were treated with increasing amounts of gemcitabine (0.1–100 μM) for 24 h (n = 4) and/or 10 or 100 ng/ml TRAIL for 4 h for BxPC-3 and MIA PaCa-2 cells and 6 h for PANC-1 cells (n = 4). All experiments were repeated three times and data are provided as means ± SEM (one representative experiment is shown). P-values were calculated using Student’s t-test to determine the statistical significance of the difference between a, b untreated cells and cells treated with either 1000 μM gemcitabine or 1000 ng/ml TRAIL, respectively (ns: P > 0.05, *P < 0.05, **P < 0.01) and c–e cells treated with 100 μM gemcitabine and cells treated with 100 μM gemcitabine plus 100 ng/ml TRAIL (***P < 0.001)

Back to article page